Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07094685 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer

Study acronym: SENIOR-HN
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Eligibility criteria expanded, about 12 wordsv5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Nov 1, 2025 to Nov 18, 2025
    • Site details revised
    v4
  3. Start date: Oct 1, 2025 to Nov 1, 2025
    • Primary completion date: Jul 1, 2027 to Aug 1, 2027
    • Study completion date: Oct 1, 2030 to Nov 1, 2030
    v3
  4. Start date: Sep 1, 2025 to Oct 1, 2025
    • Primary completion date: Jun 1, 2027 to Jul 1, 2027
    • Study completion date: Sep 1, 2030 to Oct 1, 2030
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial tests how well ivonescimab before surgery works in treating patients with stage II-IV head and neck cancer that can be removed by surgery (resectable). Ivonescimab is a bispecific monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A bispecific monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens).
Trial Details
NCT Number NCT07094685
Lead Sponsor University of Michigan Rogel Cancer Center
Collaborators: Summit Therapeutics
Conditions
(from sponsor)		 Advanced Head and Neck Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Carcinoma, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma, Stage IV Head and Neck Cutaneous Squamous Cell Carcinoma
Enrollment 28 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov